Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti‐diabetic therapies
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
New‐onset atrial fibrillation (NAF) is increased in the type 2 diabetic patient because of the presence of the metaboli syndrome and increased sympathetic activity. This results in inflammation, endothelial dysfunction and myocardial steatosis which, in turn, lead to atrial fibrosis and dilatation. The end result is the development of structural and electrical atrial remodeling. Drugs that lower insulin resistance, particularly pioglitazone, decrease the incidence of NAF while drugs that, through hypoglycaemia, stimulate the sympathetic nervous system, insulin and secretagogues, increase the incidence of NAF. Currently there is no evidence that GLP‐1 agonists, SGLT2 inhibitors and DPP‐4 inhibitors either accelerate or decelerate the development of NAF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“04% with placebo.(73) When the participants were categorized according to the presence or absence of heart failure, there was a significantly higher prevalence of AF in those with heart failure (14.”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 2×
“The EXAMINE and TIMI 53 studies resulted in similar borderline findings concerning the effect of DPP-4 inhibitors on the incidence of NAF.(77,78) In the randomized, double-blinded, prospective, placebo-controlled EXAMINE study, in which the DPP-4 inhibitor alogliptin was compared to standard of care in patients with T…”
ResultBenjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 2×
“The EXAMINE and TIMI 53 studies resulted in similar borderline findings concerning the effect of DPP-4 inhibitors on the incidence of NAF.(77,78) In the randomized, double-blinded, prospective, placebo-controlled EXAMINE study, in which the DPP-4 inhibitor alogliptin was compared to standard of care in patients with T…”
BackgroundResultObesity and the risk of new-onset atrial fibrillation
Wang, T. J. (2004) · JAMA · doi:10.1001/jama.292.20.2471 · Cited by 1,427 · cited 1×
“In the Framingham cohort study, for each unit increase in BMI, there was a 4% to 5% increase in the risk of AF.(47) This association appears to occur via left atrial stretch, atrial fibrosis,”
MethodZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort
Pathak, R. K., Middeldorp, M. E., Meredith, M., Mehta, A. B., Mahajan, R., Wong, C. X., Twomey, D., Elliott, A. D., Kalman, J. M., Abhayaratna, W. P., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.002 · Cited by 1,036 · cited 1×
“groups that lost <10%, while weight fluctuations of >5% offset this benefit.(55) Bariatric surgical intervention in the Swedish Obese Subjects”
BackgroundDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Abed, H. S., Wittert, G. A., Leong, D. P., Shirazi, M. G., Bahrami, B., Middeldorp, M. E., Lorimer, M. F., Lau, D. H., Antic, N. A., Brooks, A. G., et al. (2013) · JAMA · doi:10.1001/jama.2013.280521 · Cited by 776 · cited 1×
“001), and a decrease in left atrial area and inter-ventricular septal thickness.(56) In the long-term”
BackgroundHuxley, R. R., Lopez, F. L., Folsom, A. R., Agarwal, S. K., Loehr, L. R., Soliman, E. Z., Maclehose, R., Konety, S., & Alonso, A. (2011) · Circulation · doi:10.1161/circulationaha.110.009035 · Cited by 697
Autonomic tone variations before the onset of paroxysmal atrial fibrillation
Bettoni, M., & Zimmermann, M. (2002) · Circulation · doi:10.1161/01.cir.0000018443.44005.d8 · Cited by 534 · cited 1×
“There is usually increased sympathetic activity followed by a compensatory, but not corrective, increase in vagal activity.(30,31) In addition, as the result of hypoglycaemia and sympathetic stimulation, especially in the early morning, there is QTc prolongation that generates atrial ectopic beats that are potential p…”
BackgroundThe Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation
Tedrow, U. B., Conen, D., Ridker, P. M., Cook, N. R., Koplan, B. A., Manson, J. E., Buring, J. E., & Albert, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.029 · Cited by 500
Atrial fibrillation and obesity—results of a meta-analysis
Wanahita, N., Messerli, F. H., Bangalore, S., Gami, A. S., Somers, V. K., & Steinberg, J. S. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.10.004 · Cited by 474 · cited 1×
“of 16 studies, Wanahita et al found a 49% increase in risk with a BMI above 30 kg/m(2).(54) In the Framingham cohort study, for each unit increase in BMI, there was a 4% to 5% increase in the risk of AF.”
BackgroundWatanabe, H., Tanabe, N., Watanabe, T., Darbar, D., Roden, D. M., Sasaki, S., & Aizawa, Y. (2008) · Circulation · doi:10.1161/circulationaha.107.744466 · Cited by 427
Chow, E., Bernjak, A., Williams, S., Fawdry, R. A., Hibbert, S., Freeman, J., Sheridan, P. J., & Heller, S. R. (2014) · Diabetes · doi:10.2337/db13-0468 · Cited by 403 · cited 1×
“This points to hypoglycaemia as being a major contributor to the development of NAF, as has been shown in other studies.(32,69,70) Almost all GLP-1 agonists modestly increase the heart rate, which could be interpreted as the result of stimulation of the sympathetic”
ResultHypoglycemia and cardiovascular risks
Frier, B. M., Schernthaner, G., & Heller, S. R. (2011) · Diabetes Care · doi:10.2337/dc11-s220 · Cited by 381 · cited 2×
“This points to hypoglycaemia as being a major contributor to the development of NAF, as has been shown in other studies.(32,69,70) Almost all GLP-1 agonists modestly increase the heart rate, which could be interpreted as the result of stimulation of the sympathetic”
BackgroundResultBoettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318 · cited 1×
“A possible explanation is that pioglitazone is more effective reducing fibrosis as evidenced by studies of non-alcoholic steatohepatitis.(65)”
BackgroundDiabetes mellitus, glycemic control, and risk of atrial fibrillation
Dublin, S., Glazer, N. L., Smith, N. L., Psaty, B. M., Lumley, T., Wiggins, K. L., Page, R. L., & Heckbert, S. R. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1340-y · Cited by 310
Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., Woodward, M., Cooper, M., Harrap, S., Hamet, P., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp055 · Cited by 239 · cited 1×
“increase in total mortality, a 77% increase in cardiovascular death and a 68% increase in heart failure.(5) The greatest risk with the combina-”
BackgroundLee, A. K., Warren, B., Lee, C. J., McEvoy, J. W., Matsushita, K., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetes Care · doi:10.2337/dc17-1669 · Cited by 226 · cited 1×
“In contrast, a prospective cohort analysis of 1209 participants with diabetes from the Atherosclerosis Risk in Communities (ARIC) Study, found no association between SH and NAF.(35)”
ResultChang, S.-H., Wu, L.-S., Chiou, M.-J., Liu, J.-R., Yu, K.-H., Kuo, C.-F., Wen, M.-S., Chen, W.-J., Yeh, Y.-H., & See, L.-C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0123-x · Cited by 225 · cited 1×
“0001).(59) Again utilizing the NHRID, over 12 000 non-insulin dependent diabetic patients, of whom 34% used thiazolidinediones (TZDs), were”
MethodPersson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13077 · Cited by 212
Fatemi, O., Yuriditsky, E., Tsioufis, C., Tsachris, D., Morgan, T., Basile, J., Bigger, T., Cushman, W., Goff, D., Soliman, E. Z., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.07.045 · Cited by 173
Stahn, A., Pistrosch, F., Ganz, X., Teige, M., Koehler, C., Bornstein, S., & Hanefeld, M. (2014) · Diabetes Care · doi:10.2337/dc13-0600 · Cited by 173
Metabolic syndrome: a sympathetic disease?
Schlaich, M., Straznicky, N., Lambert, E., & Lambert, G. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70033-6 · Cited by 171
Aksnes, T. A., Schmieder, R. E., Kjeldsen, S. E., Ghani, S., Hua, T. A., & Julius, S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.10.025 · Cited by 144
Type 2 diabetes mellitus and risk of incident atrial fibrillation in women
Schoen, T., Pradhan, A. D., Albert, C. M., & Conen, D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.030 · Cited by 106 · cited 2×
“These studies augment findings from the Women's Health Study which showed that the significant relationship between T2DM and AF was probably explained by associated risk factors and not by hyperglycaemia itself.(16) In a Swedish community-based cross-sectional observational study, the age-adjusted prevalence of AF was…”
BackgroundResultDahlqvist, S., Rosengren, A., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Kosiborod, M., Svensson, A.-M., & Lind, M. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30262-0 · Cited by 70 · cited 1×
“In a prospective case-control study of type 1 diabetic patients, the risk of developing AF was only slightly increased in men, was non-significantly increased by 50% in women, and was very significantly increased in those with renal complications, suggesting that the presence of hypertension, and not of hyperglycaemia…”
Result
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
“) extracted data from the included studies as follows: (1) the author surname, year of publication, and study design; (2) patient characteristics and follow-up durations; (3) interventions; and (4) outcomes of interest.”
MethodLee, T.-W., Lee, T.-I., Lin, Y.-K., Chen, Y.-C., Kao, Y.-H., & Chen, Y.-J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03648-y · Cited by 27
Fauchier, L., Boriani, G., de Groot, J. R., Kreutz, R., Rossing, P., & Camm, A. J. (2021) · EP Europace · doi:10.1093/europace/euab184 · Cited by 22
Metadata
- Authors
- Bell, D. S. H., & Goncalves, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-09-25
- Volume
- 21
- Issue
- 2
- Pages
- 210-217
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2888632254
- Cited by
- 139
- References
- 30
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.